14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ATHA vs IRD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Opus Genetics, Inc. (IRD) on higher Unified Composite conviction (56.2/100 HOLD vs. 39.9/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while IRD wins 3–2 across the 6-pillar growth and valuation breakdown. ATHA trades at $6.75 (N/M Forward P/E, 0.0% operating margin) versus IRD at $3.94 (12.0x Forward P/E, -777.7% operating margin).
Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. IRD 39.9/100 SELL) and 6.17β · 241% Vol risk profile, whereas IRD leads top-line expansion (-63.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IRD is in a Breakdown options structure phase (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHA vs IRD. Trailing 12-month operating profitability (ATHA 0.0% vs IRD -777.7%) and valuation multiples (ATHA N/M vs IRD 12.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $392.4M market capitalization and -777.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ATHA vs IRD Key Questions & Quantitative Answers
As of Nov 16, 2026, Athira Pharma, Inc. (ATHA) captures the overall head-to-head institutional edge over Opus Genetics, Inc. (IRD) on higher Unified Composite conviction (56.2/100 HOLD vs. 39.9/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while IRD wins 3–2 across the 6-pillar growth and valuation breakdown. ATHA trades at $6.75 (N/M Forward P/E, 0.0% operating margin) versus IRD at $3.94 (12.0x Forward P/E, -777.7% operating margin). Growth vs. Quality Trade-Off: ATHA earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. IRD 39.9/100 SELL) and 6.17β · 241% Vol risk profile, whereas IRD leads top-line expansion (-63.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ATHA trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IRD is in a Breakdown options structure phase (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IRD leads the Growth & Scale pillar: ATHA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IRD at -63.1% YoY revenue growth and +0.0% YoY earnings growth on $7.9M TTM revenue (N/A gross margin, -777.7% operating margin). On trailing 12-month operating scale, ATHA generates N/A in USD-normalized revenue versus $7.9M for IRD. In operating R&D and SG&A reinvestment, ATHA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IRD.
IRD screens cheaper on headline valuation multiples. ATHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IRD trades at 12.0x Forward P/E, 12.0x Trailing P/E, N/M PEG, and 42.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATHA (-89.4% ROE) versus IRD (-615.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ATHA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.17β · 241% Vol realized risk). By comparison, IRD carries 123.1% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.